Pfizer
Mylan and Upjohn merger will create a new entity: Viatris
November 13, 2019Manufacturing and Production, Research and Development, Sales and Marketing Mylan, Pfizer, Upjohn, Viatris, pharma
The name for the new company emerging out of the merger between Pharma firm Mylan and Pfizer division Upjohn has …
Pfizer’s tofacitinib hits main goal in Phase 3 juvenile idiopathic arthritis study
November 12, 2019Manufacturing and Production, Research and Development Pfizer, pharma, tofacitinib
Pfizer has lifted the lid on new Phase 3 data exploring the efficacy of tofacitinib in the treatment of juvenile …
Pfizer and Merck KGaA’s Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial
November 8, 2019Medical Communications, Research and Development Bavencio, Merck KGaA, Pfizer, pharma
Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …
Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer
October 29, 2019Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma
Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …
Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis
October 14, 2019Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma
Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …
Tony Coles appointed to Pfizer Spinout Cerevel as CEO
September 10, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cerevel, Pfizer, pharma
Cerevel Therapeutics, a pharmaceutical company dedicated to treating neurological diseases, has appointed renowned biotechnology leader Tony Coles as Chief Executive …
Pfizer recall two batches of migraine drug Relpax
August 16, 2019Medical Communications FDA, Pfizer, Relpax, migraine, pharma, recall
Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination. In a statement on the …
Top Ten most popular articles on Pharmafile.com this week!
August 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, CAR T, CAR-T, Eli Lilly, Lexicon, Medicare, Novartis, Pfizer, Sanofi, pharma
This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The …
Pfizer’s sickle cell drug flops at Phase 3 trial
August 6, 2019Manufacturing and Production, Sales and Marketing Pfizer, Sickle cell, clinical trials, pharma, reset
Pfizer has said its sickle cell drug rivipansel failed to meet its primary endpoint or key secondary endpoints in a …
GSK closes the deal with Pfizer over $9.8 billion consumer healthcare merger
August 1, 2019Sales and Marketing GSK, Pfizer, merger, pharma
The $9.8 billion joint venture between major pharma firms GlaxoSmithKline and Pfizer to merge their consumer health operations has come …
Pfizer to combine off-patent drug unit Upjohn with Mylan
July 30, 2019Manufacturing and Production M&A, MA, Mylan, Pfizer, Upjohn, biosimilars, generics, mergers
Pfizer’s off-patent drug unit Upjohn is combining with Mylan to create a new global pharmaceutical company focused on the low-price …
Top Ten most popular articles on Pharmafile.com this week
July 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biohaven, FDA, Lyrica, NICE, Pfizer, UK, US, pharma, top ten
At the end of a week that could certainly be called “eventful” here in the UK – one that saw …
Elizabeth Warren calls on Albert Bourla to reveal detail of appointment of former FDA commissioner Scott Gottlieb to Pfizer’s board
July 25, 2019Business Services, Medical Communications Albert Bourla, Elizabeth Warren, FDA, Pfizer, Scott Gottlieb, pharma
Elizabeth Warren has called on Pfizer to reveal the details of Scott Gottlieb’s appointment to the company’s Board of Directors.
FDA approves Pfizer’s biosimilar version of Genentech’s Rituxan
July 24, 2019Research and Development FDA, Pfizer, Rituxan, Ruxience, biosimilars, pharma
Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin …
FDA approves nine generic versions of Pfizer’s Lyrica
July 23, 2019Manufacturing and Production, Sales and Marketing FDA, Lyrica, Pfizer, pharma
The FDA has given its approval to the first generic versions of Pfizer’s Lyrica (pregabalin), it has emerged, giving the …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
